✦ LIBER ✦

Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients

✍ Scribed by Spilios Manolakopoulos; Athanasia Striki; Melanie Deutsch; Maria Mela; Ioannis Ketikoglou; Dimitrios Tzourmakliotis; Emanuel K. Manesis; George V. Papatheodoridis

Book ID: 111239621
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 197 KB
Volume: 31
Category: Article
ISSN: 0106-9543
DOI: 10.1111/j.1478-3231.2011.02616.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

504 Twenty-four months combination thera

504 Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Long-term therapy with adefovir dipivoxi

Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine

✍ S. MANOLAKOPOULOS; S. BETHANIS; S. KOUTSOUNAS; J. GOULIS; J. VLACHOGIANNAKOS; E. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

521 Long-term antiviral therapy with lam

521 Long-term antiviral therapy with lamivudine (LAM) and salvage adefovir dipivoxil (ADV) improves the outcome of patients with HBeAg-negative chronic hepatitis B (CHBe-)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Focus: Long-term treatment with lamivudi

Focus: Long-term treatment with lamivudine in HBeAg negative patients with chronic hepatitis B: To switch or not to switch?

✍ Daniel Shouval 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Clinical course and predictive factors o

Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients

✍ Mashu Aizawa; Akihito Tsubota; Kiyotaka Fujise; Keiko Tatsuzawa; Midori Kono; Sa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract The aims of this study were to assess the long‐term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV‐DNA <2.6 log copies/ml at 12 months of

Long-term outcomes of add-on adefovir di

Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B

✍ Takashi Toyama; Hisashi Ishida; Hiromi Ishibashi; Hiroshi Yatsuhashi; Makoto Nak 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB